A possible relationship of natural killer T cells with humoral immune response to 23-valent pneumococcal polysaccharide vaccine in clinical settings

被引:7
|
作者
Miyasaka, Tomomitsu
Aoyagi, Tetsuji [2 ]
Uchiyama, Binei [3 ]
Oishi, Kazunori [4 ]
Nakayama, Toshinori [5 ]
Kinjo, Yuki [6 ]
Miyazaki, Yoshitsugu [6 ]
Kunishima, Hiroyuki [2 ]
Hirakata, Yoichi [2 ]
Kaku, Mitsuo [2 ]
Kawakami, Kazuyoshi [1 ]
机构
[1] Tohoku Univ, Grad Sch Med, Dept Med Microbiol Mycol & Immunol, Aoba Ku, Sendai, Miyagi 9808575, Japan
[2] Tohoku Univ, Grad Sch Med, Dept Infect Control & Lab Diagnost, Sendai, Miyagi 9808575, Japan
[3] Katta Gen Hosp, Div Resp Dis, Shiroishi, Miyagi, Japan
[4] Osaka Univ, Microbial Dis Res Inst, Dept Special Pathogens, Lab Clin Res Infect Dis, Suita, Osaka 565, Japan
[5] Chiba Univ, Grad Sch Med, Dept Med Immunol, Chiba, Japan
[6] Natl Inst Infect Dis, Dept Chemotherapy & Mycoses, Tokyo, Japan
关键词
Pneumococcal polysaccharide vaccine; Antibody production; NKT cells; CD1D-RESTRICTED NKT CELLS; STREPTOCOCCUS-PNEUMONIAE; PANDEMIC INFLUENZA; BACTEREMIA; ACTIVATION; INDUCTION; ANTIGENS; ANTIBODY; SUBSETS; MODEL;
D O I
10.1016/j.vaccine.2012.03.007
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Pneumococcal polysaccharide vaccine (PPV), a type-2 thymus-independent antigen, induces the activation of B cells by directly triggering their antigen receptors. Although this type of antigen generally does not undergo class switching from IgM to IgG, PPV has been known to induce IgG2 in vaccinated subjects, which suggests the possible involvement of certain innate immune lymphocytes supporting the activation of B cells and their class switching. In the present study, we addressed the possibility that natural killer (NK) T cells are involved in Ab production caused by PPV. We measured serum levels of IgG against pneumococcal capsular polysaccharides and the numbers of CD4(+), CD8(+) and CD4(-)CD8(-) double negative (ON) invariant NKT (iNKT) cells and CD3(+)CD56(+) NKT cells in the peripheral blood before and after PPV injection. IgG was increased after PPV injection, peaking at 4 weeks after injection in serotypes 6B, 19F and 23F and at 3 months in serotype 14. Low responders, whose serum concentrations of IgG peaked at less than double their original levels, constituted 16%, 13%, 13% and 16% of vaccinated subjects with regard to serotypes 613, 14, 19F and 23F, respectively. A significant positive correlation was detected between an increase in ON iNKT cells and the elevation of anti-serotype 14 IgG; in serotype 19F, DN iNKT cells were more markedly increased in responders than in low responders. These results suggest that DN iNKT cells may be involved in IgG production caused by vaccination against pneumococcal capsular polysaccharides. (c) 2012 Elsevier Ltd. All rights reserved.
引用
收藏
页码:3304 / 3310
页数:7
相关论文
共 50 条
  • [31] Predictors of serological non-response to the 13-valent pneumococcal conjugate vaccine followed by the 23-valent polysaccharide vaccine among adults living with HIV
    Tinggaard, Michaela
    Slotved, Hans-Christian
    Jorgensen, Charlotte Svaerke
    Kronborg, Gitte
    Benfield, Thomas
    VACCINE, 2023, 41 (30) : 4414 - 4421
  • [32] Cost-effectiveness of vaccinating the elderly and at-risk adults with the 23-valent pneumococcal polysaccharide vaccine or 13-valent pneumococcal conjugate vaccine in the UK
    Jiang, Yiling
    Gauthier, Aline
    Keeping, Sam
    Carroll, Stuart
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2014, 14 (06) : 913 - 927
  • [33] IMMUNOGENICITY AND SAFETY OF A 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE IN HEALTHY-CHILDREN AND IN CHILDREN AT INCREASED RISK OF PNEUMOCOCCAL INFECTION
    LEE, HJ
    KANG, JH
    HENRICHSEN, J
    KONRADSEN, HB
    JANG, SH
    SHIN, HY
    AHN, HS
    CHOI, Y
    HESSEL, L
    NAM, SW
    VACCINE, 1995, 13 (16) : 1533 - 1538
  • [34] Cost-effectiveness of a 23-valent pneumococcal polysaccharide vaccine immunization programme for the elderly in Shanghai, China
    Zhao, Daijun
    Tobe, Ruoyan Gai
    Cui, Min
    He, Jinchun
    Wu, Bin
    VACCINE, 2016, 34 (50) : 6158 - 6165
  • [35] Kinetics of IgM and IgA Antibody Response to 23-Valent Pneumococcal Polysaccharide Vaccination in Healthy Subjects
    Schuetz, Katharina
    Hughes, Richard G.
    Parker, Antony
    Quinti, Isabella
    Thon, Vojtech
    Cavaliere, Monica
    Wuerfel, Martina
    Herzog, Wilhelm
    Gessner, J. Engelbert
    Baumann, Ulrich
    JOURNAL OF CLINICAL IMMUNOLOGY, 2013, 33 (01) : 288 - 296
  • [36] Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 18-49 years of age, naive to 23-valent pneumococcal polysaccharide vaccine
    Bryant, K. A.
    Frenck, R.
    Gurtman, A.
    Rubino, J.
    Treanor, J.
    Thompson, A.
    Jones, T. R.
    Sundaraiyer, V.
    Baxter, L. M.
    Gruber, W. C.
    Emini, E. A.
    Scott, D. A.
    Schmoele-Thoma, B.
    VACCINE, 2015, 33 (43) : 5854 - 5860
  • [37] Immunogenicity of a 23-valent pneumococcal polysaccharide vaccine in elderly residents of a long-term care facility
    Valenzuela B., M. Teresa
    Altuzarra H., Rogelio
    Trucco A., Olivia
    Villegas R., Rodrigo
    Inostroza S., Jaime
    Granata S., Paulo
    Fleiderman V., Jose
    Maggi C., Leonardo
    BRAZILIAN JOURNAL OF INFECTIOUS DISEASES, 2007, 11 (03) : 322 - 326
  • [38] Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in patients with chronic pulmonary diseases A matched case-control study
    Vila-Corcoles, Angel
    Ochoa-Gondar, Olga
    Rodriguez-Blanco, Teresa
    Gutierrez-Perez, Antonia
    Vila-Rovira, Angel
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2012, 8 (05) : 639 - 644
  • [39] The Immunogenicity of 7-Valent Pneumococcal Conjugate Vaccine versus 23-Valent Polysaccharide Vaccine in Adults Aged 50-80 Years
    Goldblatt, David
    Southern, Jo
    Andrews, Nick
    Ashton, Lindsey
    Burbidge, Polly
    Woodgate, Sarah
    Pebody, Richard
    Miller, Elizabeth
    CLINICAL INFECTIOUS DISEASES, 2009, 49 (09) : 1318 - 1325
  • [40] Effectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23) against Pneumococcal Disease in the Elderly: Systematic Review and Meta-Analysis
    Falkenhorst, Gerhard
    Remschmidt, Cornelius
    Harder, Thomas
    Hummers-Pradier, Eva
    Wichmann, Ole
    Bogdan, Christian
    PLOS ONE, 2017, 12 (01):